Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
D

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Alone Suggests IO Treatment Option?

By Xth Eurasian Hematology-Oncology Congress FEATURING Dilek Erdem
By Xth Eurasian Hematology-Oncology Congress FEATURING Dilek Erdem
34 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

09:50
Incyte

Managing Chronic GVHD Master Class Series: Best Practices at 100 Day…

Feat. C. Cutler
Skin
14:32

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Xth Eurasian Hematology-Oncology Congress

Z. Turna

36 views
06:35

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Xth Eurasian Hematology-Oncology Congress

Z. Turna

27 views
21:19

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Xth Eurasian Hematology-Oncology Congress

S. Seber

256 views
05:25

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Xth Eurasian Hematology-Oncology Congress

D. Erdem

34 views
15:44

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Xth Eurasian Hematology-Oncology Congress

D. Erdem

49 views